información sobre la mifepristona, el metotrexate y el misoprostol

inicio preguntas

antecedentes legales



You can read this page in English; Vous pouvez aussi lire cette page en français;  
You can read this page in Arabic
You can read this website in Persian

  • ACOG Practice Bulletin. 2001; no. 26.
  • merican Psychological Association, Task Force on Mental Health and Abortion. Report of the Task Force on Mental Health and Abortion. Washington, DC: Author, 2008.
  • Baird D. Mode of action of medical methods of abortion. JAMWA. 2000; 35(3): S121-126.
  • Barbosa R, Arilha M. The Brazilian experience with Cytotec. Studies in Family Planning. 1993; 24(4): 236-240.
  • Bebbington M, Kent N, Lim K, Gagnon A, Delisle M, Tessier F, Wilson R. A randomized controlled trial comparing two protocols for the use of misoprostol in midtrimester pregnancy termination. Am J Obstet. Gynecol. 2002; 187(4): 853-857.
  • Benson J, Clark K, Gerhardt A, Randall L, Dudley S. Early abortion services in the United States: Ensuring service availability, remaining on the cutting edge of technology, and responding to client demand. Chapel Hill, NC: IPAS, 2001.
  • Beral V, Bull D, Doll R, et al. Breast cancer and abortion: Collaborative reanalysis of data from 53 epidemiological studies, including 83,000 women with breast cancer from 16 countries. Lancet. 2004;363(9414):1007-16.
  • Blanchard K, Winikoff B, Ellertson C. Misoprostol used alone for the termination of early pregnancy: A review of the evidence. Contraception 1999; 59: 209-217.
  • Blanchard K, Clark S, Winikoff B, Gaines G, Kabani G, Shannon C. Misoprostol for women's health: A review. Am J Obstet Gynecol. 2002; 99(2): 316-332.
  • Boonstra H. Mifepristone in the United States: Status and future. The Guttmacher Report on Public Policy. 2002: 4-7.
  • Bugalho A, Mocumbi S, Faúndes A, David E. Termination of pregnancies of <6 weeks gestation with a single dose of 800 µg of vaginal misoprostol. Contraception. 2000; 61: 47-50.
  • Bygdeman M, Gemzell K, Marions L. Medical termination of early pregnancy: The Swedish experience. JAMWA. 2000; 35(3): S195-196.
  • Carbonell J, Rodrigues J, Aragón S, Velazco A, Tanda R, Sánchez C, Barambio S, Chami S, Valero F. Vaginal misoprostol 1000 µg for early abortion. Contraception 2001; 63: 131-136.
  • Carbonell Esteve J, Varela L, Velazco L, Cabezas A, Tanda R, Sánchez C. Vaginal misoprostol for late first trimester abortion. Contraception. 1998; 57: 329-333.
  • Carbonell Esteve J, Varela L, Velazco A., Tanda R, Cabezas E, Sánchez C. Early abortion with 800 µg of misoprostol by the vaginal route. Contraception. 1999; 59; 219-225.
  • Charles V, Polis C, Sridhara S, Blum R. Abortion and long-term mental health outcomes: a systematic review of the evidence. Contraception 2008;78:436-50.
  • Clark S, Ellertson C, Winikoff B. Is medical abortion acceptable to all American women: The impact of sociodemographic characteristics on the acceptability of mifepristone-misoprostol abortion. JAMWA. 2000; 35(3): S177-182.
  • Cheng L, Gülmezoglu A, Piaggio G, Ezcurra E, Van Look P. Interventions for emergency contraception. Cochrane Database Syst Rev. 2008, Issue 2.
  • Costa S, Vessey M. Misoprostol and illegal abortion in Rio de Janeiro, Brazil. Lancet. 1993; 341: 1258-1261.
  • Coyaji K. Early medical abortion in India: Three studies and their implications for abortion services. JAMWA. 2000; 35(3): S191-194.
  • Creinin M, Schwartz J, Guido R, Pymar H. Early pregnancy failure-Current management concepts. Obstetrical and Gynecological Survey. 2001; 56(2): 105-113.
  • Creinin M. Medical abortion regimens: historical context and overview. Am J Obstet Gynecol. 2000; 183: S3-S9.
  • Creinin M, Pymar H. Medical abortion alternatives to mifepristone. JAMWA. 2000; 35(3): S127-132.
  • Creinin M, Carbonell J, Schwartz J, Varela L, Tanda R. A randomized trial of the effect of moistening misoprostol before vaginal administration when used with methotrexate for abortion. Contraception. 1999; 59(1): 217-221.
  • Ellertson C, Elul B, Winikoff B. Can women use medical abortion without medical supervision? Reproductive Health Matters. 1997; 9: 149-161.
  • Ellertson C, Waldman S. The mifepristone-misoprostol regimen for early medical abortion. Current Women's Health Reports 2001; 1: 184-190.
  • Elul B, Pearlman E, Sorhaindo A, Simonds W, Westhoff C. In-depth interviews with medical abortion clients: Thoughts on the method and home administration of misoprostol. JAMWA. 2000; 35(3): S169-172.
  • Ewart W, Winikoff B. Toward safe and effective medical abortion. Science. 1998; 281: 520-521.
  • Finer L, Henshaw S. Abortion incidence and services in the United States in 2000. Perspectives on Sexual and Reproductive Health. 2003; 35(1): 6-15.
  • Glick E. Surgical Abortion. Reno, NV: West End Women's Medical Group, 1998.
  • Hamoda H, Ashok P, Stalder C, Flett G, Kennedy E, Templeton A. A randomized trial of mifepristone (10 mg) and levonorgestrel for emergency contraception. Obstet Gynecol. 2004;104:1307-13.
  • Harper C, Ellertson C, Winikoff B. Could American women use mifepristone-misoprostol pills safely with less medical supervision? Contraception 2002; 65(2): 133-142.
  • Harvey S, Sherman C, Bird S, Warren J. Understanding medical abortion: Policy, politics, and women's health. Eugene, OR: Center for the Study of Women in Society, 2002.
  • Henshaw S, Finer L. The accessibility of abortion services in the United States, 2001. Perspectives on Sexual and Reproductive Health. 2003; 35(1): 16-24.
  • Jain J, Dutton C, Harwood B, Meckstroth K, Mishell D. A prospective randomize, double-blinded, placebo-controlled trial comparing mifepristone and vaginal misoprostol to vaginal misoprostol alone for elective termination of early pregnancy. Human Reproduction 2002; 17(6): 1477-1482.
  • Jain J, Kuo J, Mishell D. A comparison of two dosing regimens of intravaginal misoprostol for second-trimester pregnancy termination. Am J Obstet. Gynecol. 1999; 93(4): 571-575.
  • Jones R, Darroch J, Henshaw S. Patterns in the socioeconomic characteristics of women obtaining abortion in 2000-2001. Perspectives on Sexual and Reproductive Health. 2002; 34(5): 226-235.
  • Jones R, Henshaw S. Mifepristone for early medical abortion: Experiences in France, Great
  • Britain and Sweden. Perspectives on Sexual and Reproductive Health. 2002; 34(3): 154-161.
  • Kahn J, Becker B, MacIsaac L, et al. The efficacy of medical abortion: a meta-analysis. Contraception. 2000; 61:29-40.
  • Kruse B. Advanced practice clinicians and medical abortion: Increasing access to care. JAMWA. 2000; 35(3): S167-168.
  • Melbye M, Wohlfahrt J, Olsen J, et al. Induced abortion and the risk of breast cancer. N Engl J Med. 1997; 336(2): 81-85.
  • National Abortion Federation. Early medical abortion with mifepristone and other agents: Overview and protocol recommendations. Washington, DC: NAF, 2002.
  • Newhall E, Winikoff B. Abortion with mifepristone and misoprostol: Regimens, efficacy, acceptability and future directions. Am J Obstet Gyncol. 2000; 183(2): S44-53.
  • Ngai S, Tang O, Chan Y, Ho P. Vaginal misoprostol alone for medical abortion up to 9 weeks of gestation: Efficacy and acceptability. Human Reproduction. 2000; 15(5): 1159-1162.
  • Philip N, Shannon C, and Winikoff B. Misoprostol and teratogenicity: Reviewing the evidence–Report of a meeting. Robert H. Ebert Program on Critical Issues in Reproductive Health Publication Series. New York: Population Council, 2003.
  • Pymar H, Creinin M. Alternatives to mifepristone regimens for medical abortion. Am J Obstet Gyncol. 2000; 183(2). S54-64.
  • Rodger M, Baird D. Blood loss following induction of early abortion using mifepristone (RU 486) and a prostaglandin analog (gemeprost). Contraception. 1997; 56(3): 165-168.
  • Rosing M, Archbald C. The knowledge, acceptability, and use of misoprostol for self-induced medical abortion in an urban US population. JAMWA. 2000; 35(3): S183-185.
  • Schaff E, Fielding S. A comparison of the abortion rights mobilization and Population Council trials. JAMWA. 2000; 35(3): S137-140.
  • Schaff E, Fielding S, Westhoff C, Ellertson C, Eisinger Stadalius L, Fuller L. Vaginal misoprostol administered 1, 2, or 3 days after mifepristone for early medical abortion: A randomized trial. JAMWA. 2000; 284(15): 1948-1953
  • Shangchun, W. Medical abortion in China. JAMWA. 2000; 35(3): S197-199.
  • Spitz I, Bardin C, Benton L, and Robbins A. Early pregnancy termination with mifepristone and misoprostol in the United States. N Eng J Med. 1998; 338: 1241-1247.
  • Stewart F, Wells E, Flinn S, Weitz T. Early medical abortion: Issues for practice. San Francisco, CA: UCSF, Center for Reproductive Health Research and Policy, 2000.
  • Steinberg J, Russo N. Abortion and anxiety: what's the relationship? Soc Sci Med 2008;67:238–52.
  • Tang O, Miao B, Lee S, Ho P. Pilot study on the use of repeated doses of sublingual misoprostol in termination of pregnancy up to 12 weeks gestation: Efficacy and acceptability.Human Reproduction 2002; 17(3): 654-658.
  • Tang O, Ho P. Pilot study on the use of sublingual misoprostol for medical abortion. Contraception 2001; 64: 315-317.
  • Ulmann A. The development of mifepristone: A pharmaceutical drama in three acts. JAMWA. 2000; 35(3): S117-120.
  • von Hertzen H, Piaggio G, Ding J, Chen J, Song S, Bártfai G, Ng E, Gemzell-Danielsson K, Oyunbileg A, Wu S, Cheng W, Lüdicke F, Pretnar-Darovec A, Kirkman R, Mittal S, Khomassuridze A, Apter D, Peregoudov A. Low dose mifepristone and two regimens of levonorgestrel for emergency contraception: a WHO multicentre randomised trial. Lancet 2002;360:1803-10.
  • von Hertzen H. Research on regimens for early medical abortion. JAMWA. 2000; 35(3): S133-136.
  • Weitz T, Foster A, Ellertson C, Grossman D, Stewart F. “Medical” and “surgical” abortion: Rethinking the modifiers. Contraception 2004:69;77-78.
  • World Health Organization Task Force on Post-ovulatory Methods of Fertility Regulation. Termination of pregnancy with reduced doses of mifepristone. BMJ. 1993; 307 (6903): 532-537.


Su acceso y uso de la página web está sujeto a ciertos términos de uso. Al visitar el sitio, usted acepta, sin limitaciones ni condición alguna, estos términos. Lea nuestra declaración de privacidad. El sitio a sido actualizado enero 2015.